explore -WSS

explore

author：hotspot 2025-09-14 21:55:05 - browse：1666

Andrea Coravos, managing director at ICON, speaks at the STAT Breakthrough Summit West in San Francisco Thursday as Ida Sim, chief research informatics officer at UCSF, looks on. Sarah Gonzalez for STAT

Just because the Food and Drug Administration has given the Apple Watch and other wearable devices the OK to market the health benefits of their tracking and algorithms doesn’t mean that the data they generate are useful for either patients or their doctors, experts said Thursday at the STAT Breakthrough Summit West in San Francisco.

“Yesterday, I saw a patient with type 2 diabetes who has a continuous glucose monitor, and so she’s been tracking her blood sugar every five minutes,” said Ida Sim, a primary care physician and chief research informatics officer at the University of California, San Francisco. “[I] sat with her for almost an hour yesterday. I couldn’t get to her CGM data — she had it on her phone, but the report goes into a website that I didn’t have the login to, and it hadn’t been downloaded into my electronic medical record. So all this tracking data, I didn’t have it.”

Not only do clinicians not have the ability to access data that their patients want to use to guide their care, but primary care doctors often don’t know how to interpret that firehose of data, said Sim. She asked some of her endocrinology research colleagues how they use that data and they explained the calculations needed to create biomarker metrics from them. That made the data largely useless to her as a doctor, and it was frustrating.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Case highlights the risks of experimental stem cell therapy

hotspot

entertainment

WSS

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Venture capitalist Bob Kocher on the state of digital health

Glen Campbell's doctor discusses his public struggle with Alzheimer's

AstraZeneca bets AAV gene therapy will still deliver the goods

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

NYU Langone launches private ChatGPT for its health care data

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Drug firms test therapies to halt Alzheimer’s before symptoms arise

23andMe had bad news about my health. I wish a person had delivered it

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Medical records are filled with copy

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

It's time to retire 'poor historian' from clinicians' vocabularies

Bright Health sells Medicare Advantage business to Molina

Addiction experts warn against a second 'war on drugs'

hotspot

Second House panel advances two

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Feds fine Medicare Advantage plans for overcharging members

It's time to retire 'poor historian' from clinicians' vocabularies

How a symptom of dementia informs our understanding of creativity

In science, is the line between industry and academia shifting?

Wikipedia

hotspot

entertainment

leisure time